Travere Therapeutics, INC

Travere Therapeutics announced a planned leadership transition, with Bradley L. Campbell succeeding Eric Dube, Ph.D. as President and CEO, effective December 1, 2026.

Travere Therapeutics announced robust second quarter 2026 financial results, highlighted by significant FILSPARI sales growth and strategic pipeline expansion.

Travere Therapeutics, Inc. announced the upcoming retirement of its Chief Accounting Officer, Sandra Calvin, with Vice President, Controller John Torell slated to succeed her.

Travere Therapeutics announced the upcoming retirement of its Chief Research Officer, William Rote, Ph.D., effective February 17, 2027, with Dr. Jula Inrig to assume expanded R&D leadership responsibilities.

Travere Therapeutics has entered into a material definitive agreement, securing an exclusive license from Everest Medicines for the development and commercialization of civorebrutinib outside of China and certain Asian countries.

Travere Therapeutics held its 2026 Annual Meeting of Stockholders, approving an amendment to its 2018 Equity Incentive Plan to increase authorized shares and ratifying the selection of its independent auditor.

Travere Therapeutics announced a significant increase in net product sales, primarily driven by FILSPARI, alongside substantial growth in operating expenses and a net loss for the quarter.

Travere Therapeutics announced a significant increase in net product sales, driven by FILSPARI, and provided updates on its clinical pipeline.

Travere Therapeutics, Inc. announced significant revenue growth in the third quarter of 2025, driven by strong FILSPARI sales and milestone payments, while narrowing its net loss for the nine-month period.

Travere Therapeutics reports strong revenue growth driven by FILSPARI, significantly reducing its net loss and advancing key pipeline programs.

Travere Therapeutics' Q1 2025 shows significant revenue growth driven by FILSPARI, alongside progress in regulatory submissions and clinical trials.

Travere Therapeutics' Q3 2024 results show increased product sales driven by FILSPARI, alongside strategic pipeline advancements and a voluntary pause in a key clinical trial.

Travere Therapeutics' 2025 annual report highlights significant revenue growth from FILSPARI, progress in its FSGS and HCU programs, and strategic partnerships, despite ongoing clinical and market challenges.

Travere Therapeutics achieved full FDA approval for FILSPARI in IgAN and advanced its pipeline, while managing financial performance amidst restructuring and strategic shifts.

Travere Therapeutics' 2023 annual report highlights the commercial launch of FILSPARI, progress in clinical trials, and a strategic reorganization.

William E. Rote, Chief Research Officer of Travere Therapeutics, Inc., sold 209,048 shares of common stock on September 15, 2026.

Peter Heerma, EVP, CHIEF COMMERCIAL OFFICER of Travere Therapeutics, Inc., sold 283,189 shares of common stock on September 15, 2026.

Jula Inrig, EVP, Head of R&D & CMO of Travere Therapeutics, Inc., sold 44,674 shares of common stock on September 15, 2026.

Elizabeth E Reed, Chief Legal Officer and GC of Travere Therapeutics, Inc., sold 37,500 shares of common stock on September 15, 2026.

Eric M Dube, CHIEF EXECUTIVE OFFICER and a Director of Travere Therapeutics, Inc., sold 400,000 shares of common stock on September 15, 2026.

Christopher R. Cline, CHIEF FINANCIAL OFFICER of Travere Therapeutics, Inc., sold 50,508 shares of common stock on September 15, 2026.

Travere Therapeutics has issued its 2026 proxy statement detailing proposals for director elections, an equity incentive plan amendment, and executive compensation advisory votes.

Travere Therapeutics announces its 2025 Annual Meeting of Stockholders to be held on May 15, 2025, to vote on director elections, equity incentive plan amendments, executive compensation, and auditor ratification.

Travere Therapeutics announces its 2025 Annual Meeting of Stockholders to be held on May 15, 2025, featuring proposals including director elections, equity incentive plan amendments, executive compensation approval, and auditor ratification.

Travere Therapeutics will hold its annual stockholders meeting on May 8, 2024, to vote on director elections, equity incentive plan amendments, executive compensation, and auditor ratification.

Travere Therapeutics is holding its annual meeting on May 8, 2024, to vote on director elections, an equity incentive plan amendment, executive compensation, and auditor ratification.

Armistice Capital, LLC and Steven Boyd have jointly reported beneficial ownership of 1,572,539 shares, representing 1.67% of the outstanding common stock of Travere Therapeutics, Inc.

Bank of America Corporation has reported a beneficial ownership of 5.8% in Travere Therapeutics, Inc., holding over 5.4 million shares as of June 30, 2026.

State Street Corporation has disclosed beneficial ownership of 4.6% of Travere Therapeutics Inc.'s common stock as of June 30, 2026.

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 5.27% in Travere Therapeutics, Inc., holding 4,897,417 shares of common stock.

Vanguard Capital Management has reported beneficial ownership of 5.09% of Travere Therapeutics Inc.'s common stock as of March 31, 2026.

The Vanguard Group has reported a 0% beneficial ownership in Travere Therapeutics Inc. following an internal corporate realignment.